[1] |
付晶, 张瑞鹏, 许美馨, 等. 中国西南地区某大型三甲综合医院脓毒症住院患者的流行病学分析[J]. 中华危重病急救医学, 2024, 36(6):574-577.
|
[2] |
CHIU C, LEGRAND M. Epidemiology of sepsis and septic shock[J]. Curr Opin Anaesthesiol, 2021, 34(2): 71-76. doi:10.1097/aco.0000000000000958
doi: 10.1097/aco.0000000000000958
|
[3] |
FORD J S, MORRISON J C, KYAW M, et al. The Effect of Severe Sepsis and Septic Shock Management Bundle (SEP-1) Compliance and Implementation on Mortality Among Patients With Sepsis: A Systematic Review[J]. Ann Intern Med, 2025, 178(4): 543-557. doi:10.7326/annals-24-02426
doi: 10.7326/annals-24-02426
|
[4] |
DESPOSITO L, BASCARA C. Review: Sepsis guidelines and core measure bundles[J]. Postgrad Med, 2024, 136(7): 702-711. doi:10.1080/00325481.2024.2388021
doi: 10.1080/00325481.2024.2388021
|
[5] |
王丽娜,王华成,张一彤,等.血清IL-6对脓毒症病情判断的作用[J].中国热带医学,2018,18(8):827-829.
|
[6] |
THEOBALD V, SCHMITT F C F, MIDDEL C S, et al. Triggering receptor expressed on myeloid cells-1 in sepsis, and current insights into clinical studies[J]. Crit Care, 2024, 28(1): 17. doi:10.1186/s13054-024-04798-2
doi: 10.1186/s13054-024-04798-2
|
[7] |
LIANG J, CAI Y, SHAO Y. Comparison of presepsin and Mid-regional pro-adrenomedullin in the diagnosis of sepsis or septic shock: A systematic review and meta-analysis[J]. BMC Infect Dis, 2023, 23(1): 288. doi:10.1186/s12879-023-08262-4
doi: 10.1186/s12879-023-08262-4
|
[8] |
LIU Y C, YAO Y, YU M M, et al. Frequency and mortality of sepsis and septic shock in China: A systematic review and meta-analysis[J]. BMC Infect Dis, 2022, 22(1): 564. doi:10.1186/s12879-022-07543-8
doi: 10.1186/s12879-022-07543-8
|
[9] |
冯珂, 勾燚, 吕博辉, 等. 严重创伤患者发生脓毒症的危险因素分析[J]. 中华创伤杂志, 2024, 40(8): 727-733.
|
[10] |
丁一凡, 李晓青, 李雪珠, 等. 脓毒症集束化治疗对患者预后的影响及其实施现状[J]. 中华医学杂志, 2025, 105(11): 820-826.
|
[11] |
SARTINI C, LANDONI G, BELLETTI A, et al. Beyond the Surviving Sepsis Campaign Guidelines: A systematic review of interventions affecting mortality in sepsis[J]. Panminerva Med, 2024, 66(1): 55-62. doi:10.23736/s0031-0808.23.04986-8
doi: 10.23736/s0031-0808.23.04986-8
|
[12] |
HUA T, YAO F, WANG H, et al. Megakaryocyte in sepsis: The trinity of coagulation, inflammation and immunity[J]. Crit Care, 2024, 28(1): 442. doi:10.1186/s13054-024-05221-6
doi: 10.1186/s13054-024-05221-6
|
[13] |
NEDEVA C. Inflammation and Cell Death of the Innate and Adaptive Immune System during Sepsis[J]. Biomolecules, 2021, 11(7): 1011. doi:10.3390/biom11071011
doi: 10.3390/biom11071011
|
[14] |
ZANDERS L, KNY M, HAHN A, et al. Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting[J]. J Cachexia Sarcopenia Muscle, 2022, 13(1): 713-727. doi:10.1002/jcsm.12867
doi: 10.1002/jcsm.12867
|
[15] |
HAN T, LIANG T, LIU R, et al. The association between interleukin-8 gene polymorphism and the risk of sepsis in older adults[J]. J Orthop Surg Res, 2024, 19(1): 804. doi:10.1186/s13018-024-05296-5
doi: 10.1186/s13018-024-05296-5
|
[16] |
BARICHELLO T, GENEROSO J S, SINGER M, et al. Biomarkers for sepsis: More than just fever and leukocytosis-a narrative review[J]. Crit Care, 2022, 26(1): 14. doi:10.1186/s13054-021-03862-5
doi: 10.1186/s13054-021-03862-5
|
[17] |
YAJNIK V, MAAROUF R. Sepsis and the microcirculation: The impact on outcomes[J]. Curr Opin Anaesthesiol, 2022, 35(2): 230-235. doi:10.1097/aco.0000000000001098
doi: 10.1097/aco.0000000000001098
|
[18] |
TORRES L K, PICKKERS P, VAN DER POLL T. Sepsis-Induced Immunosuppression[J]. Annu Rev Physiol, 2022, 84: 157-181. doi:10.1146/annurev-physiol-061121-040214
doi: 10.1146/annurev-physiol-061121-040214
|
[19] |
CÓRNEO E D S, MICHELS M, DAL-PIZZOL F. Sepsis, immunosuppression and the role of epigenetic mechanisms[J]. Expert Rev Clin Immunol, 2021, 17(2): 169-176. doi:10.1080/1744666x.2021.1875820
doi: 10.1080/1744666x.2021.1875820
|
[20] |
吴健锋. 脓毒症免疫抑制的监测和治疗进展[J]. 中山大学学报(医学版),2020,41(1):30-36.
|
[21] |
王亚南, 王梦晴, 任云飞, 等. 脓毒症免疫抑制细胞的变化及其与预后关系的研究进展[J]. 中华急诊医学杂志, 2025, 34(2): 264-271.
|
[22] |
HAMADA M, VARKOLY K S, RIYADH O, et al. Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator[J]. Biomedicines, 2024, 12(6): 1167. doi:10.3390/biomedicines12061167
doi: 10.3390/biomedicines12061167
|
[23] |
NUSSHAG C, WEI C, HAHM E, et al. suPAR links a dysregulated immune response to tissue inflammation and sepsis-induced acute kidney injury[J]. JCI Insight, 2023, 8(7): e165740. doi:10.1172/jci.insight.165740
doi: 10.1172/jci.insight.165740
|
[24] |
NUSSHAG C, WEI C, HAHM E, et al. suPAR links a dysregulated immune response to tissue inflammation and sepsis-induced acute kidney injury[J]. JCI Insight, 2023, 8(7): e165740. doi:10.1172/jci.insight.165740
doi: 10.1172/jci.insight.165740
|
[25] |
NARENDRA S, WYAWAHARE M, ADOLE P S. Presepsin vs. Procalcitonin as Predictors of Sepsis Outcome[J]. J Assoc Physicians India, 2022, 70(11): 11-12. doi:10.5005/japi-11001-0146
doi: 10.5005/japi-11001-0146
|
[26] |
BAIK S M, PARK J, KIM T Y, et al. Validation of presepsin measurement for mortality prediction of sepsis: A preliminary study[J]. Acute Crit Care, 2022, 37(4): 527-532. doi:10.4266/acc.2022.00150
doi: 10.4266/acc.2022.00150
|
[27] |
LEE G B, LEE J W, YOON S H, et al. Plasma presepsin for mortality prediction in patients with sepsis-associated acute kidney injury requiring continuous kidney replacement therapy[J]. Kidney Res Clin Pract, 2024, 43(4): 457-468. doi:10.23876/j.krcp.23.301
doi: 10.23876/j.krcp.23.301
|
[28] |
李晶,陆芹芹,崔艳飞. 血清PGC-1α水平在脓毒症致急性肾损伤诊断中的价值[J]. 实用医学杂志, 2023, 39(4):471-475. doi:10.3969/j.issn.1006-5725.2023.04.015
doi: 10.3969/j.issn.1006-5725.2023.04.015
|
[29] |
吴海燕,王宝玉,贾宝辉. 外周血游离线粒体DNA,miR-146a表达对评估脓毒症患者近期预后的价值[J]. 实用医学杂志, 2024, 40(23):3356-3361.
|